Bausch & Lomb raised its sales by 4 percent to $1.16 billion in the third quarter ended Sept. 30, as a decline in sales of ophthalmology products was offset by extra revenues of $67 million from acquisitions. The parent company, Valeant Pharmaceuticals, reported an 11 percent drop in total sales to $2.48 billion, due in part to foreign exchange losses, divestitures and discontinuations of previous businesses. The group posted a net loss of $1.22 billion for the period as compared to net income of $49.5 million in the same quarter a year ago, due primarily to a goodwill impairment charge of $1.05 billion. Adjusted Ebitda of $1.18 billion came out better than in the first and second quarters.